Document Detail

The stress of starvation: glucocorticoid restraint of beta cell development.
Jump to Full Text
MedLine Citation:
PMID:  21072627     Owner:  NLM     Status:  MEDLINE    
Developmental insults during gestation, such as under-nutrition, are known to restrict the number of beta cells that form in the fetal pancreas and are maintained in adulthood, leading to increased risk of type 2 diabetes. There are now substantial data indicating that glucocorticoids mediate this effect of under-nutrition on beta cell mass and that even at physiological levels they restrain fetal beta cell development in utero. There are emerging clues that this occurs downstream of endocrine commitment by neurogenin 3 but prior to terminal beta cell differentiation. Deciphering the precise mechanism will be important as it might unveil new pathways by which to manipulate beta cell mass that could be exploited as novel therapies for patients with diabetes.
L C Matthews; N A Hanley
Related Documents :
20579917 - Decreasing postprandial c-peptide levels over time are not associated with long-term us...
7786637 - Evidence for the synthesis of parathyroid hormone-related protein (pthrp) by nontransfo...
8545117 - Over-expression of transfected n-myc oncogene in human sknsh neuroblastoma cells down-r...
20332437 - Sulindac sulfone induces a decrease of beta-catenin in hnscc.
17701297 - 3-d nanofibrous electrospun multilayered construct is an alternative ecm mimicking scaf...
23100637 - Bench scale conversion of 3-cyanopyidine to nicotinamide using resting cells of rhodoco...
Publication Detail:
Type:  Comment; Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-11-12
Journal Detail:
Title:  Diabetologia     Volume:  54     ISSN:  1432-0428     ISO Abbreviation:  Diabetologia     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-01-07     Completed Date:  2011-05-02     Revised Date:  2013-07-03    
Medline Journal Info:
Nlm Unique ID:  0006777     Medline TA:  Diabetologia     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  223-6     Citation Subset:  IM    
Endocrinology and Diabetes Group, School of Biomedicine, Manchester Academic Health Sciences Centre, AV Hill Building, University of Manchester, Manchester M13 9PT, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Basic Helix-Loop-Helix Transcription Factors / metabolism
Body Composition / physiology
Cell Differentiation / physiology
Corticosterone / blood
Eating / physiology*
Fetal Growth Retardation / metabolism,  physiopathology
Glucocorticoids / metabolism*
Glucose Tolerance Test
Insulin / metabolism
Insulin-Secreting Cells / metabolism*
Islets of Langerhans / metabolism
Nerve Tissue Proteins / metabolism
Polymerase Chain Reaction
Receptors, Glucocorticoid / genetics,  metabolism*
Grant Support
088566//Wellcome Trust
Reg. No./Substance:
0/Basic Helix-Loop-Helix Transcription Factors; 0/Glucocorticoids; 0/Insulin; 0/NEUROG3 protein, human; 0/Nerve Tissue Proteins; 0/Receptors, Glucocorticoid; 50-22-6/Corticosterone
Comment On:
Diabetologia. 2011 Feb;54(2):350-9   [PMID:  20857084 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Diabetologia
ISSN: 0012-186X
ISSN: 1432-0428
Publisher: Springer-Verlag, Berlin/Heidelberg
Article Information
Download PDF
© The Author(s) 2010
Received Day: 27 Month: 9 Year: 2010
Accepted Day: 6 Month: 10 Year: 2010
Electronic publication date: Day: 12 Month: 11 Year: 2010
pmc-release publication date: Day: 12 Month: 11 Year: 2010
Print publication date: Month: 2 Year: 2011
Volume: 54 Issue: 2
First Page: 223 Last Page: 226
ID: 3017310
PubMed Id: 21072627
Publisher Id: 1963
DOI: 10.1007/s00125-010-1963-x

The stress of starvation: glucocorticoid restraint of beta cell development
L. C. MatthewsAff1
N. A. HanleyAff1 Address:
Endocrinology and Diabetes Group, School of Biomedicine, Manchester Academic Health Sciences Centre, AV Hill Building, University of Manchester, Manchester, M13 9PT UK

The last 20 years have seen marked interest in the hypothesis that environmental insults to the fetus can programme future cardiovascular and metabolic disorders in the offspring [1, 2]. The ‘fetal origins of adult disease’ hypothesis was borne of epidemiological data associating gestational under-nutrition and low birthweight with future conditions, including type 2 diabetes. As adult euglycaemia is dependent on gaining an adequate number of insulin-secreting beta cells (‘beta cell mass’) as well as their subsequent maintenance, mechanistic studies have since queried how such insults might compromise beta cell development within the fetal pancreas [3].

Major understanding of beta cell specification has arisen from studying signalling pathways and nuclear transcription factors, largely in rodents, that regulate the sequential commitment of multipotent progenitors down different pancreatic lineages to terminal differentiation [4, 5]. Variation in the balance of activity of these pathways and transcription factors within defined developmental window periods alters beta cell specification relative to other pancreatic cell types. However, superimposed on this specification ‘blueprint’, it is also possible to conceptualise a more subtle rheostatic control from nutrients or hormones to amplify or restrain the numbers of cells appropriately differentiating to a particular fate.

In this issue of Diabetologia, further evidence is provided from Bréant, Blondeau and colleagues for the important role of glucocorticoids (GCs) as critical hormones mediating the effect of under-nutrition on reducing beta cell mass [6]. Work by the same authors and others has previously linked maternal under-nutrition in rats with raised fetal levels of corticosterone (the main GC in rodents, comparable with cortisol in human) to an estimated halving of beta cells in the pancreas [7, 8]. Maternal adrenalectomy and baseline corticosterone replacement almost entirely abrogated this effect, implying the causal link with adrenocortical hormones [7]. Here, in corroboration, inactivating the glucocorticoid receptor (GR) in the developing mouse pancreas blocked the reduction in beta cell mass caused by under-nutrition [6]. Indeed during normal gestation, loss of GR led to a significant increase in beta cells [6, 8]. The combined data demonstrate several key points. There is a central role for GC–GR signalling in restraining beta cell mass, and this occurs physiologically not just pathologically. Whereas restored or increased beta cell mass came from causing GR inactivation by Pdx1 expression (an early event in pancreas development), that controlled by insulin expression (a late, beta cell specific event) had no effect. The regulatory sequences from both genes are widely used in mice to induce Cre recombinase production and are well validated [9, 10]. Although, theoretically, GR inactivation at duodenal sites of Pdx1 expression might be responsible, the more likely interpretation is that GC–GR action is influential after the specification of Pdx1-positive pancreatic progenitor cells but prior to terminal beta cell differentiation.

In addition to reducing beta cell development, GCs increased gene expression associated with exocrine development. Transcripts of the pro-exocrine transcription factor, Ptf1a, amylase and carboxypeptidase A were all approximately doubled while those for the endocrine commitment transcription factor, Neurogenin 3 (Ngn3), and later markers of beta cell differentiation were slightly reduced [6]. Similarly, dexamethasone, a potent synthetic GC, increased exocrine tissue in rat explants in vitro [8]. This suggests that gestational under-nutrition via GC–GR signalling might switch multipotent pancreatic progenitors to an exocrine fate at the expense of endocrine cells. Dexamethasone can cause transdifferentiation between cell types [11]. Inducing endocrine–exocrine perturbation is possible during mouse pancreas development prior to embryonic day (E) 14, by which stage exocrine specification from multipotent progenitors is largely complete [12, 13]. However, timing is everything and several lines of evidence suggest that the critical window period for under-nutrition and the effect of GCs is later in pancreas development.

Compromised beta cell function in rat is observed following maternal dexamethasone treatment in the final week of gestation but not at earlier stages [14]. In the mouse, pancreatic GR production rises between E14.5 and E16.5, peaks at E16.5 and has fallen sharply by E17.5 [15]. Following GR inactivation, mouse pancreas appeared normal at E15.5 during major endocrine commitment due to transient Ngn3 production [16, 17]. Taken together, these data imply that GC restriction of beta cell development occurs perhaps coincident with, but more likely after, Ngn3 production and prior to that of insulin. This interpretation of a relatively late effect of GCs on endocrine differentiation would also dictate that the exocrine observations are either secondary or in parallel rather than part of an endocrine–exocrine phenotypic switch mechanism.

It seems feasible that the major role of GR signalling is to restrain cell proliferation at later stages of beta cell differentiation. Following Pdx1-regulated GR inactivation the authors in this issue report increased BrdU incorporation as a marker of recent proliferation in insulin-positive cells as well as in nearby insulin-negative cells (Fig. 6d in [6]). Further immunohistochemistry would be useful to identify these insulin-negative BrdU-positive cells by co-localisation with transcription factors produced after Ngn3, such as neurogenic differentiation 1 (Neuro1), paired box gene 6 (Pax6), ISL1 transcription factor, LIM/homeodomain (Isl1), NK2 transcription factor related, locus 2 (Drosophila, Nkx2.2), NK6 homeobox 1 (Nkx6.1) and v-maf musculoaponeurotic fibrosarcoma oncogene family, protein A (avian) (MafA), as well as other endocrine hormone markers. Potential involvement of the MODY 1 gene, HNF4α is intriguing. Dexamethasone causes a switch in use from the P2 to the P1 promoter of Hnf4α and increases transcript levels in the liver [18]. Both promoters are active in the human fetal pancreas making HNF4α expression potentially sensitive to GCs during beta cell development [19]. Inactivating mutations in HNF4a that later give rise to diabetes paradoxically present with hyperinsulinaemia and macrosomia at birth [20]; cellular levels of other genes in the insulin secretion pathway are unchanged, implying that loss of HNF4α increases the number of fetal beta cells. Piecing these datasets together, GCs could act during beta cell development to increase functional HNF4α which, despite being required in postnatal beta cells, seems unexpectedly to restrain fetal beta cell mass. Accurately identifying the genetic targets of GR action will be complex: the function of the nuclear hormone receptor varies widely according to the setting and includes both activation and repression [21]; as well as directly regulating transcription, GR binding to DNA can profoundly modify chromatin structure, affecting potential access to adjacent DNA for a range of other transcription factors; it can influence transcriptional activity of other factors via protein–protein interaction off DNA [21]; and genetic targets vary according to whether GC delivery is pulsatile or continuous [22, 23].

For relevance in diabetes it will be important to translate these findings from rodent models. In considering potential programming of human fetuses by GCs, a lot of attention has focussed on placental transfer of maternal cortisol during the third trimester of gestation and the adequacy or otherwise of the placental enzyme type 2 11β-hydroxysteroid dehydrogenase (HSD11B2), which inactivates cortisol to cortisone [14, 24]. Although late gestation is the period that most profoundly influences birthweight, this phase and maternal transfer may not be the most important factors for GC programming of beta cell mass. Timed with the first wave of beta cell differentiation and islet formation [25, 26], the presence of NGN3 protein has been most consistently reported late in the first trimester and early in the second trimester of human gestation [2729]. Reports of the transcription factor later in pregnancy are conflicting, with some groups unable to detect it [30]. During this period of 8–14 weeks post-conception, transfer of maternal cortisol across the placenta seems of secondary importance to fetal adrenocortical production; female fetuses with congenital adrenal hyperplasia due to 21-hydroxylase deficiency would otherwise not be so profoundly cortisol-deficient as to virilise [31, 32]. In contrast, the first trimester human fetal adrenal is remarkable for its cortisol secretion, with GC action via GR in the anterior pituitary able to regulate ACTH secretion [33]. This raises the possibility that factors even subtly varying human fetal cortisol production, such as polymorphic variations in key enzymes, may influence pancreatic beta cell development. Concordant with these combined speculations, data from people born during or soon after the Dutch winter famine of 1944–1945 have demonstrated that impaired glucose tolerance in later life with seemingly deficient insulin secretion correlated most strongly with food restriction during their early and mid-gestation, but not the last trimester [34].

In summary, there has been clear progress in resolving the mechanistic complexity of gestational under-nutrition on beta cell development down to a role for a single hormone, now robustly corroborated by genetic inactivation of its nuclear hormone receptor [6]. Alongside the value of understanding such risk factors for type 2 diabetes, discovering hormones and other secreted factors that regulate beta cell development may offer clues for new drug development to enhance beta cell mass. In the case of GR, novel ligands are an area of intense pharmaceutical activity [35, 36]. Further mechanistic understanding of GR action may even throw up new pathways for potential manipulation. However, regardless of such possibilities, as molecular research has tended to focus us ever deeper into the nucleus, it is perhaps comforting—as diabetologists and endocrinologists—that ‘old-fashioned’ hormone communication between our favourite organs remains important during gestation as well as postnatally.


The authors receive support from the Manchester National Institute for Health Research Biomedical Research Centre. L. C. Matthews is a University of Manchester Stepping Stones Fellow. N. A. Hanley is a Wellcome Trust Senior Fellow in Clinical Science in addition to receiving funding from the Biotechnology and Biological Sciences Research Council, the Engineering and Physical Sciences Research Council, and Stem Cells for Safer Medicine.

Duality of interest The authors declare that there is no duality of interest associated with this manuscript.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

1.. Hales CN,Barker DJ. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesisDiabetologiaYear: 19923559560110.1007/BF004002481644236
2.. Barker DJ,Gluckman PD,Godfrey KM,Harding JE,Owens JA,Robinson JS. Fetal nutrition and cardiovascular disease in adult lifeLancetYear: 199334193894110.1016/0140-6736(93)91224-A8096277
3.. Bréant B,Gesina E,Blondeau B. Nutrition, glucocorticoids and pancreas developmentHorm ResYear: 200665Suppl 39810416612121
4.. Puri S,Hebrok M. Cellular plasticity within the pancreas—lessons learned from developmentDev CellYear: 20101834235610.1016/j.devcel.2010.02.00520230744
5.. Zaret KS,Grompe M. Generation and regeneration of cells of the liver and pancreasScienceYear: 20083221490149410.1126/science.116143119056973
6.. Valtat B, Dupuis C, Zenaty D, Sing-Estivalet A, Tronche F, Bréant B, Blondeau B (2010) Genetic evidence of the programming of beta cell mass and function by glucocorticoids in mice. Diabetologia. doi:10.1007/s00125-010-1898-2
7.. Blondeau B,Lesage J,Czernichow P,Dupouy JP,Bréant B. Glucocorticoids impair fetal beta-cell development in ratsAm J Physiol Endocrinol MetabYear: 2001281E59259911500315
8.. Gesina E,Tronche F,Herrera P,et al. Dissecting the role of glucocorticoids on pancreas developmentDiabetesYear: 2004532322232910.2337/diabetes.53.9.232215331541
9.. Gu G,Dubauskaite J,Melton DA. Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitorsDevelopmentYear: 20021292447245711973276
10.. Herrera PL. Adult insulin- and glucagon-producing cells differentiate from two independent cell lineagesDevelopmentYear: 20001272317232210804174
11.. Shen CN,Slack JM,Tosh D. Molecular basis of transdifferentiation of pancreas to liverNat Cell BiolYear: 2000287988710.1038/3504652211146651
12.. Schaffer AE,Freude KK,Nelson SB,Sander M. Nkx6 transcription factors and Ptf1a function as antagonistic lineage determinants in multipotent pancreatic progenitorsDev CellYear: 2010181022102910.1016/j.devcel.2010.05.01520627083
13.. Solar M,Cardalda C,Houbracken I,et al. Pancreatic exocrine duct cells give rise to insulin-producing beta cells during embryogenesis but not after birthDev CellYear: 20091784986010.1016/j.devcel.2009.11.00320059954
14.. Seckl JR. Prenatal glucocorticoids and long-term programmingEur J EndocrinolYear: 2004151Suppl 3U49U6210.1530/eje.0.151U04915554887
15.. Speirs HJ,Seckl JR,Brown RW. Ontogeny of glucocorticoid receptor and 11beta-hydroxysteroid dehydrogenase type-1 gene expression identifies potential critical periods of glucocorticoid susceptibility during developmentJ EndocrinolYear: 200418110511610.1677/joe.0.181010515072571
16.. Schwitzgebel VM,Scheel DW,Conners JR,et al. Expression of neurogenin3 reveals an islet cell precursor population in the pancreasDevelopmentYear: 20001273533354210903178
17.. Gesina E,Blondeau B,Milet A,et al. Glucocorticoid signalling affects pancreatic development through both direct and indirect effectsDiabetologiaYear: 2006492939294710.1007/s00125-006-0449-317001468
18.. Nyirenda MJ,Dean S,Lyons V,Chapman KE,Seckl JR. Prenatal programming of hepatocyte nuclear factor 4alpha in the rat: a key mechanism in the ‘foetal origins of hyperglycaemia’?DiabetologiaYear: 2006491412142010.1007/s00125-006-0188-516570165
19.. Harries LW,Locke JM,Shields B,et al. The diabetic phenotype in HNF4A mutation carriers is moderated by the expression of HNF4A isoforms from the P1 promoter during fetal developmentDiabetesYear: 2008571745175210.2337/db07-174218356407
20.. Pearson ER,Boj SF,Steele AM,et al. Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A genePLoS MedYear: 20074e11810.1371/journal.pmed.004011817407387
21.. Revollo JR,Cidlowski JA. Mechanisms generating diversity in glucocorticoid receptor signalingAnn NY Acad SciYear: 2009117916717810.1111/j.1749-6632.2009.04986.x19906239
22.. Desvergne B,Heligon C. Steroid hormone pulsing drives cyclic gene expressionNat Cell BiolYear: 2009111051105310.1038/ncb0909-105119724259
23.. Stavreva DA,Wiench M,John S,et al. Ultradian hormone stimulation induces glucocorticoid receptor-mediated pulses of gene transcriptionNat Cell BiolYear: 2009111093110210.1038/ncb192219684579
24.. Seckl JR,Holmes MC. Mechanisms of disease: glucocorticoids, their placental metabolism and fetal ‘programming’ of adult pathophysiologyNat Clin PractYear: 2007347948810.1038/ncpendmet0515
25.. Piper K,Brickwood S,Turnpenny LW,et al. Beta cell differentiation during early human pancreas developmentJ EndocrinolYear: 2004181112310.1677/joe.0.181001115072563
26.. Polak M,Bouchareb-Banaei L,Scharfmann R,Czernichow P. Early pattern of differentiation in the human pancreasDiabetesYear: 20004922523210.2337/diabetes.49.2.22510868939
27.. Sugiyama T,Rodriguez RT,McLean GW,Kim SK. Conserved markers of fetal pancreatic epithelium permit prospective isolation of islet progenitor cells by FACSProc Natl Acad Sci USAYear: 200710417518010.1073/pnas.060949010417190805
28.. Lyttle BM,Li J,Krishnamurthy M,et al. Transcription factor expression in the developing human fetal endocrine pancreasDiabetologiaYear: 2008511169118010.1007/s00125-008-1006-z18491072
29.. Piper Hanley K,Hearn T,Berry A,et al. In vitro expression of NGN3 identifies RAB3B as the predominant Ras-associated GTP-binding protein 3 family member in human isletsJ EndocrinolYear: 201020715116110.1677/JOE-10-012020807725
30.. Yebra M,Montgomery AM,Diaferia GR,et al. Recognition of the neural chemoattractant Netrin-1 by integrins alpha6beta4 and alpha3beta1 regulates epithelial cell adhesion and migrationDev CellYear: 2003569570710.1016/S1534-5807(03)00330-714602071
31.. Hanley NA,Arlt W. The human fetal adrenal cortex and the window of sexual differentiationTrends Endocrinol MetabYear: 20061739139710.1016/j.tem.2006.10.00117046275
32.. Krone N,Hanley NA,Arlt W. Age-specific changes in sex steroid biosynthesis and sex developmentBest Pract Res Clin Endocrinol MetabYear: 20072139340110.1016/j.beem.2007.06.00117875487
33.. Goto M,Piper Hanley K,Marcos J,et al. In humans, early cortisol biosynthesis provides a mechanism to safeguard female sexual developmentJ Clin InvestigYear: 200611695396010.1172/JCI2509116585961
34.. Rooij SR,Painter RC,Phillips DI,et al. Impaired insulin secretion after prenatal exposure to the Dutch famineDiab CareYear: 2006291897190110.2337/dc06-0460
35.. Raalte DH,Ouwens DM,Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options?Eur J Clin InvestYear: 200939819310.1111/j.1365-2362.2008.02067.x19200161
36.. Schacke H,Berger M,Rehwinkel H,Asadullah K. Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic indexMol Cell EndocrinolYear: 200727510911710.1016/j.mce.2007.05.01417630119


E Embryonic day
GC Glucocorticoid
GR Glucocorticoid receptor
NGN3 Neurogenin 3

Article Categories:
  • Commentary

Keywords: Keywords Beta cell, Corticosterone, Cortisol, Development, Glucocorticoid, Glucocorticoid receptor, Human, Insulin, Mouse, Neurogenin 3, Pancreas, Under-nutrition.

Previous Document:  Design of Small-Molecule Smac Mimetics as IAP Antagonists.
Next Document:  Targeting of the actin cytoskeleton by insecticidal toxins from Photorhabdus luminescens.